Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330607 | 0.91 | CDC7 (0.31) | MAP3K7 | |
| SCHEMBL4339752 | 0.89 | — | — | |
| SCHEMBL3945084 | 0.87 | HTT (0.33) | — | |
| SCHEMBL4330593 | 0.85 | — | — | |
| SCHEMBL4558093 | 0.85 | PLD2 (0.35) | MAP3K7 | |
| SCHEMBL13783364 | 0.85 | L3MBTL1 (0.37) | MAP3K7 | |
| SCHEMBL5983917 | 0.83 | HPGD (0.33) | — | |
| SCHEMBL13783369 | 0.81 | PARP1 (0.35) | MAP3K7 | |
| Hydrochloric Acid SCHEMBL4334320 | 0.80 | AURKA (0.34) | — | |
| SCHEMBL4330586 | 0.80 | SLC6A9 (0.33) | MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1661897-B1 | PYRROLOPYRIMIDINONE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | TEIJIN PHARMA LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1661896-A1 | PYRROLOPYRIMIDINETHIONE DERIVATIVE | Teijin Pharma Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661897-A1 | PYRROLOPYRIMIDINONE DERIVATIVE | Teijin Pharma Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20050153992-A1 | Pyrrolopyrimidine thion derivatives | TEIJIN PHARMA LIMITED (JP) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153992-A1 | Pyrrolopyrimidine thion derivatives | GSK3B, GSK3A, GSKIP | MAP3K7 2503/4885 |
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | GSK3B, GSK3A, GSKIP | MAP3K7 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.